Mechanics Bank Trust Department Invests $288,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mechanics Bank Trust Department purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 404 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.

Several other institutional investors have also added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $42,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:REGN opened at $681.58 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The company has a market cap of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The stock’s fifty day moving average price is $738.60 and its 200-day moving average price is $948.80.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.